Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.
BACKGROUND
While the costs associated with Alzheimer's disease have been shown to be significant, there are few data relating cost of care to severity of the disease.


OBJECTIVE
We aimed to compare the costs associated with different severities of Alzheimer's disease with those incurred by control subjects over a three-month period.


METHODS
In this cross-sectional, multicentre, naturalistic analysis, non-institutionalised patients with Alzheimer's disease (128), their care-givers (128), and 56 matched controls were interviewed once to establish resource use over the previous three months. Patients were stratified into three severity groups according to their Mini Mental State Examination score. Costs were calculated from the perspective of society as a whole.


RESULTS
Over the three-month period, total mean cost per control subject (387 Pounds) was minor compared with mean cost incurred by patients with mild (6616 Pounds), moderate (10,250 Pounds) and severe (13,593 Pounds) Alzheimer's disease. Indirect cost, mainly time spent by care-givers, was the main cost component in all groups (68.6%), followed by direct medical costs (24.7%).


CONCLUSIONS
The cost of care for an Alzheimer's disease patient is directly related to the severity of the patients illness.
Souêtre
E
E
Pharmacoeconomic Research, Glaxo Wellcome Research & Development, Middlesex, UK.
Thwaites
R M
RM
Yeardley
H L
HL
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000191:economics*; D003430:Cross-Sectional Studies; D004180:Direct Service Costs; D005260:Female; D017048:Health Care Costs; D006295:Health Resources / Q000191:economics* / Q000706:statistics & numerical data; D017721:Hospital Costs; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D006113:United Kingdom